HMGB1 and hematocrit: A lot of immunomodulators, such as high-mobility group box 1 (HMGB1) inhibitor (Chen et al., 2020) and regulatory T cells therapy (Mao et al., 2017), have been used to relieve HT induced by tPA thrombolysis in animal studies.